A
Albireo
A biotechnology company, develops therapeutic drugs for gastrointestinal diseases
About Albireo
Albireo Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing novel bile acid modulators to treat rare pediatric liver diseases. The company's flagship product, odevixibat, is a potent and selective IBAT inhibitor designed to treat Progressive Familial Intrahepatic Cholestasis (PFIC), a rare genetic liver disease. Albireo operates in the biopharmaceutical market, targeting orphan liver diseases with no currently approved drug therapies. The business model revolves around research and development, clinical trials, and eventual commercialization of their proprietary drugs. Revenue is generated through product sales, licensing agreements, and potential partnerships with larger pharmaceutical companies. Albireo serves patients, healthcare providers, and the broader medical community, aiming to alleviate the pain and suffering associated with bile acid biology irregularities.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2008
- Headquarters
- Boston, United States
- Listing
- IPO 2016
- Sector
- Biotech & Life Sciences
- Power Law
- Colt$25–100M revenue
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
TPG Growth
TVM Capital Life Science
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Albireo on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Albireo on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.